Try our beta test site

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

This study has been terminated.
(Informed by manufacturer that CDB-2914 crosses blood-brain barrier invalidating Arm #3 of protocol.)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
ClinicalTrials.gov Identifier:
NCT00089414
First received: August 4, 2004
Last updated: November 2, 2016
Last verified: November 2016
  Purpose

This study will determine whether uninterrupted treatment with birth control pills over several menstrual cycles prevents severe premenstrual syndrome (PMDD).

Previous studies have shown that the hormones estrogen and progesterone regulate mood in women with MRMD. This study will use various treatment regimens with birth control pills and placebo (sugar pill) to clarify the relationships among estrogen and progesterone, the menstrual cycle, and mood.

Healthy women between 18 and 45 years of age who menstruate may be eligible for this 15-week study. Candidates are screened with a physical examination, blood and urine tests, an electrocardiogram, and 3 months of symptoms ratings to confirm MRMD.

Participants are randomly assigned to one of three treatment groups. Group 1 takes a birth control pill every day and on three occasions takes a placebo capsule. Group 2 takes a birth control pill most but not all days and on three occasions takes a placebo capsule. Group 3 takes a birth control pill every day and on three occasions takes another medication called CDB-2914 that causes menstrual bleeding to occur.

Participants come to the NIH clinic every other week for blood tests and measurement of vital signs (blood pressure, pulse, and temperature) and to complete symptoms ratings scales. Subjects who develop breakthrough bleeding (menstruation earlier than expected) will have a transvaginal ultrasound. For this procedure, a probe is inserted into the vagina for about 10 minutes. The probe gives off and receives sound waves that can be used to form a picture of the endometrium (lining of the uterus).


Condition Intervention Phase
Premenstrual Syndrome
PMS
Premenstrual Dysphoric Disorder
PMDD
Depression
Drug: Yasmin
Drug: Placebo
Drug: CDB 2914
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Treatment of Menstrually-Related Mood Disorders With Extended Versus Interrupted Oral Contraceptives

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Change in Premenstrual Tension Syndrome Scale (PMTS) Factors Associated With Premenstrual Symptoms. [ Time Frame: Every 2 weeks for 3 months ]
    The PMTS observer scales assess symptoms in ten different domains including irritability-hostility; tension; efficiency; dysphoria; moodiness; motor coordination; mental-cognitive functioning; eating habits; sexual drive and activity; physical symptoms and social impairment. They have been used to measure premenstrual symptom severity and response to treatment in several clinical trials and prevalence studies. Score ranges from no symptoms to severe symptoms on a scale of 0 to 6, with 0 being no symptoms and 6 being severely symptomatic.


Secondary Outcome Measures:
  • Change in Clinical Global Impression Scale (CGI) Factors Associated With Premenstrual Symptoms. [ Time Frame: Every 2 wks for 3 months ]
    The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication.1 The CGI provides an overall clinician-determined summary measure that takes into account all available information, including a knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. The CGI actually comprises two companion one-item measures evaluating the following: (a) severity of psychopathology from 1 to 7 and (b) change from the initiation of treatment on a similar seven-point scale, with 1 being normal/more improved and 7 being severe/worse.

  • Change in Beck Depression Inventory (BDI) Factors Associated With Premenstrual Symptoms [ Time Frame: Every 2 weeks for 3 months ]

    The Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. Total scores are interpreted per these ranges:

    0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.



Enrollment: 5
Study Start Date: July 2004
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
Drug: Yasmin
Drug administered dependent upon arm.
Other Name: a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone
Active Comparator: 2
Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
Drug: Yasmin
Drug administered dependent upon arm.
Other Name: a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone
Drug: Placebo
Active Comparator: 3
Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
Drug: Yasmin
Drug administered dependent upon arm.
Other Name: a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone
Drug: CDB 2914
Other Name: Progesterone antagonist

Detailed Description:
Results from previous protocols (#90-M-0088 and 92-M-0174) have demonstrated that women with menstrually-related mood disorder (MRMD), but not women lacking this disorder, experience mood deterioration within approximately one to two weeks after exposure to either estradiol or progesterone in the context of gonadal suppression (induced by use of the depot gonadotropin releasing hormone agonist leuprolide acetate). Preliminary results of protocol 00-M-0103 suggest that this hormone-induced depression occurs consequent to changes in gonadal steroid levels and not to simple exposure to basal levels above a critical threshold. Additionally, continued administration of hormone for three months resulted in no further symptoms subsequent to the initial precipitated episode. These data suggest the potential therapeutic benefit of extended oral contraceptive (OC) regimens with reduced pill-free intervals in MRMD to minimize the mood destabilizing effects of changing hormone levels. In this protocol we examine whether the effects of 15 weeks of continuous oral contraceptive administration causes a remission of symptoms in women with MRMD.
  Eligibility

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA (are from protocol 81-M-0126 and are as follows):
  • Subjects who meet criteria for MRMD are healthy (by physical exam, normal pelvic exam and pap smear, and normal lab values) and medication free will be included in this study.
  • Oral contraceptives (and CDB-2914 in arm #3) will not be administered to any subject with significant clinical or laboratory abnormalities.

EXCLUSION CRITERIA:

Any patient with a current axis I psychiatric diagnosis will be excluded from participating in this protocol.

Subjects taking psychotropic agents (e.g. antidepressants, anxiolytics or mood stabilizers) will likewise be excluded from the study.

Women who have received glucocorticoid or megestrol therapy within the last year (and thus may experience residual suppression of the compensatory HPA axis response to CDB-2914-induced glucocorticoid receptor antagonism) will be also excluded, albeit almost entirely on theoretical grounds.

Women who have any chronic medical conditions or are taking medications will be excluded.

Women who have a medical condition or are taking any chronic medications that may increase serum potassium levels will also be excluded.

Those patients who would be uncomfortable with extending the length of their menstrual cycles will not be enrolled in this study and will either be offered participation in another study or an outside referral for treatment in the community.

The following conditions will constitute contraindications to treatment with continuous oral contraception or the use of the progesterone antagonist, CDB-2914, and will preclude a patient's participating in this protocol:

  • history of endometriosis, or recent, rapid growth of uterine fibroid tumors (defined as doubling in size in six month period);
  • diagnosis of ill-defined, obscure pelvic lesions, particularly undiagnosed ovarian enlargement;
  • hepatic disease as manifested by abnormal liver function tests;
  • history of breast carcinoma;
  • history of pulmonary embolism or phlebothrombosis;
  • undiagnosed vaginal bleeding;
  • porphyria;
  • history of malignant melanoma;
  • history of cholecystitis or pancreatitis;
  • history of hypercholesterolemia, hypertension, diabetes, or renal disease;
  • recurrent migraine headaches (greater than or equal to 3 per year) in women 35 or older;
  • pregnancy or lactation;
  • cigarette smoking in women 35 or older, or more than 10 cigarettes per day in women under 35; or
  • use of oral, injectable, or inhaled glucocorticoids or megestrol within the last year.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00089414

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Pedro E Martinez, M.D. National Institute of Mental Health (NIMH)
  More Information

Publications:
Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00089414     History of Changes
Other Study ID Numbers: 040221  04-M-0221 
Study First Received: August 4, 2004
Results First Received: January 14, 2013
Last Updated: November 2, 2016

Keywords provided by National Institutes of Health Clinical Center (CC):
Depression
Menstrual Cycle
Gonadal Steroids
Ethinyl Estradiol
Drospirenone
Menstrually Related Mood Disorder
MRMD

Additional relevant MeSH terms:
Depression
Disease
Mood Disorders
Premenstrual Syndrome
Premenstrual Dysphoric Disorder
Behavioral Symptoms
Pathologic Processes
Mental Disorders
Menstruation Disturbances
Depressive Disorder
Estradiol
Polyestradiol phosphate
Ethinyl Estradiol
Progesterone
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Contraceptive Agents
Drospirenone and ethinyl estradiol combination
Drospirenone
Contraceptives, Oral
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Reproductive Control Agents
Contraceptive Agents, Female
Progestins
Mineralocorticoid Receptor Antagonists
Hormone Antagonists

ClinicalTrials.gov processed this record on February 20, 2017